By Mackenzie Tatananni

AbbVie's $10.9 billion acquisition of a Massachusetts-based biotech doesn't represent a pivot into new territory. Rather, it strengthens the immunology portfolio that built the drugmaker's powerhouse reputation.

Shares of Apogee Therapeutics spiked in premarket trading Monday after AbbVie said it plans to acquire all outstanding shares for $135.11 each in cash. The transaction has been approved by both companies' boards and is slated to close in the third quarter.

Apogee stock surged 48% to $133.39. AbbVie was up 1.8%.

The deal aligns with AbbVie's highly lucrative immunology business, which is largely driven by the success of its blockbuster drug Skyrizi. Last quarter, the segment brought in $7.3 billion, representing nearly half of the company's total revenue for the period.

This wasn't always the case. While Skyrizi and Rinvoq lead the portfolio today, the segment was previously anchored by Humira -- an anti-inflammatory drug that reigned as the industry's most valuable medicine for half a decade.

AbbVie lost U.S. patent exclusivity for Humira in 2023, opening the door to cheaper, "copycat" biosimilars. This sudden influx of competition triggered a steep drop in the drug's revenue.

Even AbbVie's market-leading products haven't been immune to pressure. Skyrizi faces a new threat from Johnson & Johnson's daily pill, Icotyde. While Skyrizi only requires four injections a year, Wall Street anticipates that many patients may prefer the convenience of an oral pill over an injection.

While AbbVie remains confident that demand will hold steady, it is a logical move for the company to bolster its portfolio. By doing so, AbbVie can protect its reputation as an immunology leader and double down on what has historically driven its success.

Apogee's leading drug candidate is zumilokibart, an atopic dermatitis treatment. Analysts at BMO Capital Markets recently noted that the drug appears slightly more effective than Regeneron and Sanofi's Dupixent, while also offering a more convenient dosing schedule.

As seen with drugs like Skyrizi and Icotyde, delivery methods are a key way for companies to stand out. While Dupixent requires an injection under the skin every two weeks, zumilokibart only needs to be injected every three to six months.

AbbVie itself said Monday that the deal complements its existing immunology portfolio and accelerates its "clinical presence in the respiratory space."

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

June 22, 2026 07:45 ET (11:45 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.